Apixaban, an orally available anticoagulant, inhibits SARS-CoV-2 replication by targeting its major protease in a non-competitive way
Chaves, O. A.; Sacramento, C. Q.; Fintelman-Rodrigues, N.; Temerozo, J. R.; Pereira-Dutra, F.; Mizurini, D. M.; Monteiro, R. Q.; Vazquez, L.; Bozza, P. T.; Castro-Faria-Neto, H. C.; Souza, T. M. L.
Show abstract
Anticoagulants are associated with clinical benefit against the 2019 coronavirus disease (COVID-19), preventing COVID-19 associated coagulopathy. Blood coagulation factor Xa (FXa) and SARS-CoV-2 major protease (Mpro) share over 80% homology at the three-dimensional protein level. Thus, it is worth interrogating whether there is crosstalk between inhibitors and substrates between these enzymes. Here, we found that the clinically-approved FXa inhibitor apixaban targets SARS-CoV-2 Mpro with a 21-fold higher potency than boceprevir (GC376). Apixaban displayed a non-competitive mechanism of inhibition towards Mpro, since it targets the enzyme/substrate complex and the allosteric site onto the viral protease. Enzymatic assays were further validated in infected Calu-3 cells, which reveal that apixaban decreases the production of infectious viral particles in a dose-dependent manner, with an inhibitory potency in the micromolar range. Our results are in line with the proposed early use of anticoagulants, including FXa inhibitors, to improve clinical outcome of COVID-19 patients. In this context, apixaban may display a dual mechanism of action by targeting FXa to prevent coagulopathy and, at some level, SARS-CoV-2 Mpro.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- ACE2-Targeting Monoclonal Antibody as Potent and Broad-Spectrum Coronavirus Blocker 93%
- Nelfinavir was predicted to be a potential inhibitor of 2019 nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation 92%
- An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants 92%
Similar papers in this journal
Similar papers in this journal
- Brilacidin, a COVID-19 Drug Candidate, demonstrates broad-spectrum antiviral activity against human coronaviruses OC43, 229E and NL63 through targeting both the virus and the host cell 94%
- Induction of the inflammasome by the SARS-CoV-2 accessory protein ORF9b, abrogated by small-molecule ORF9b homodimerization inhibitors 93%
- Evolving Infection Paradox of SARS-CoV-2: Fitness Costs Virulence? 92%
Similar papers in this journal
- Boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronaviruses in cell culture 95%
- Drug repurposing screening identified tropifexor as a SARS-CoV-2 papain-like protease inhibitor 94%
- Challenges for targeting SARS-CoV-2 proteases as a therapeutic strategy for COVID-19 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.